Abstract
A major limitation in finding therapeutic solutions for Alzheimers disease (AD) has been the lack of a reliable method for early diagnosis of this devastating disease. Besides the development of biomarkers in biological fluids of patients, the search for a pathology-specific neuroimaging tools is critical at the present stage in which almost 30 million people suffer this disease worldwide. Several interesting approaches have been developed, however their clinical impact has been low. One of the difficulties has been to find the proper molecular tracers to specifically tag pathognomonic lesions in AD brain, including not only amyloid aggregates but also filaments of the modified microtubule-associated protein tau. In this review, we analyze the evidence towards developing pathology-specific diagnostic tools for AD. We analyze the current evidence and clinical implications of new imaging technologies for AD, and how tau hypothesis and the amyloid cascade hypothesis will impact on these scientific efforts in the near future.
Keywords: Alzheimer's disease, PET radiotracers, brain neuroimaging, benzimidazoles, tau protein, amyloid beta, AChEIs, NIH-ADAD, SPs, APP, Amyloid Cascade Hypothesis, FTDP17-T, PS-selective
Current Alzheimer Research
Title: Molecular Targets in the Rational Design of AD Specific PET Tracers: Tau or Amyloid Aggregates?
Volume: 8 Issue: 6
Author(s): L. E. Rojo, P. A. Gaspar and R. B. Maccioni
Affiliation:
Keywords: Alzheimer's disease, PET radiotracers, brain neuroimaging, benzimidazoles, tau protein, amyloid beta, AChEIs, NIH-ADAD, SPs, APP, Amyloid Cascade Hypothesis, FTDP17-T, PS-selective
Abstract: A major limitation in finding therapeutic solutions for Alzheimers disease (AD) has been the lack of a reliable method for early diagnosis of this devastating disease. Besides the development of biomarkers in biological fluids of patients, the search for a pathology-specific neuroimaging tools is critical at the present stage in which almost 30 million people suffer this disease worldwide. Several interesting approaches have been developed, however their clinical impact has been low. One of the difficulties has been to find the proper molecular tracers to specifically tag pathognomonic lesions in AD brain, including not only amyloid aggregates but also filaments of the modified microtubule-associated protein tau. In this review, we analyze the evidence towards developing pathology-specific diagnostic tools for AD. We analyze the current evidence and clinical implications of new imaging technologies for AD, and how tau hypothesis and the amyloid cascade hypothesis will impact on these scientific efforts in the near future.
Export Options
About this article
Cite this article as:
E. Rojo L., A. Gaspar P. and B. Maccioni R., Molecular Targets in the Rational Design of AD Specific PET Tracers: Tau or Amyloid Aggregates?, Current Alzheimer Research 2011; 8 (6) . https://dx.doi.org/10.2174/156720511796717203
DOI https://dx.doi.org/10.2174/156720511796717203 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Biological Evaluation of Azomethine-dihydroquinazolinone Conjugates as Cancer and Cholinesterase Inhibitors
Medicinal Chemistry The Molecular Basis of Conantokin Antagonism of NMDA Receptor Function
Current Drug Targets Editorial [Hot Topic: Frontotemporal Lobar Degeneration and Related Disorders (Guest Editor: Barbara Borroni)]
Current Alzheimer Research Effect of Nanotechnology Approaches on Anti-retroviral Molecule: Efavirenz
Current Organic Chemistry Heart Failure and Cognitive Impairment: Clinical Relevance and Therapeutic Considerations
Current Cardiology Reviews Gene Transfer to the Central Nervous System: Current State of the Art of the Viral Vectors
Current Genomics Neopterin as a Marker for Immune System Activation
Current Drug Metabolism The Early Involvement of the Innate Immunity in the Pathogenesis of Lateonset Alzheimers Disease: Neuropathological, Epidemiological and Genetic Evidence
Current Alzheimer Research Diabetes NEP-Like Endopeptidases and Alzheimers Disease
Current Alzheimer Research ADAM10 as a Therapeutic Target for Cancer and Inflammation
Current Pharmaceutical Design Type 2 Diabetes Mellitus and Alzheimer’s Disease: Bridging the Pathophysiology and Management
Current Pharmaceutical Design Statins and Cardiovascular Diseases: From Cholesterol Lowering to Pleiotropy
Current Pharmaceutical Design Editorial: Spatial Cognition in Normal Aging, MCI and AD
Current Alzheimer Research Human Disease and Drug Pharmacology, Complex as Real Life
Current Medicinal Chemistry Emerging Potential of Natural Products as an Alternative Strategy to Pharmacological Agents Used Against Metabolic Disorders
Current Drug Metabolism From Blood-to-Brain: Regulating the Permeability of the Blood-Brain Barrier
Current Psychopharmacology Gene Therapy for Parkinsons and Alzheimers Diseases: from the Bench to Clinical Trials
Current Pharmaceutical Design Neuroinflammation, Microglia and Mast Cells in the Pathophysiology of Neurocognitive Disorders: A Review
CNS & Neurological Disorders - Drug Targets Insights Into the Molecular Aspects of Neuroprotective Bacoside A and Bacopaside I
Current Neuropharmacology PET/MR Tomographs: A Review with Technical, Radiochemical and Clinical Perspectives
Current Radiopharmaceuticals